ArticleJournal of gastrointestinal oncology2025
CYSTM1 is a potential diagnostic and prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transferrin receptor 1 is required for efficient hepatitis E virus production.PLoS pathogens · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a lethal malignancy due to the lack of reliable biomarkers for early diagnosis and prognosis. Here, we hypothesized that cysteine rich transmembrane module containing 1 (CYSTM1) could function as a potential diagnostic and prognostic biomarker and correlated with immune infiltrates in HCC. Methods: Integrating multi-omics bioinformatics analyses with experimental validation, we identified CYSTM1 as a clinically actionable biomarker. Results: We demonstrated that CYSTM1 was significantly overexpressed in HCC tissues compared to normal liver tissues. The receiver operating characteristic (ROC) curve analysis revealed that CYSTM1 had a high diagnostic value. Kaplan-Meier survival analysis indicated that high CYSTM1 expression correlated with poorer overall survival (OS). The expression level of CYSTM1 was significantly associated with the infiltration level of CD4 Conclusions: Collectively, our study established CYSTM1 as a dual-purpose biomarker for HCC diagnosis and prognosis, offering a therapeutic target for TLR pathway modulation. The immune-linked mechanism uncovered here addressed a critical gap in HCC personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.